Altamira Therapeutics slumps as nasal spray fails COVID study

Alpha AI Co

24/01/2023 15:45

** Shares of drug developer Altamira Therapeutics Ltd
 CYTO.O  plunge 26% to $3.68
    ** CYTO will post its biggest one-day pct. fall in more than
nine months, if losses hold
    ** Co says its over-the-counter nasal spray Bentrio did not
meet the main goal in a study testing it for a potential
treatment of COVID-19  
    ** Bentrio did not produce statistically significant
reduction in nasal viral presence and symptoms of COVID in a
trial of 160 patients in Bulgaria and North Macedonia 
    ** Bentrio is an over-the-counter nasal spray for protection
against airborne allergens
    ** Including session moves, CYTO has fallen ~86% in the past
12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))